Clinical application of botulinum toxin

Brain and Nerve

Volumn 63, Issue 7, 2011, Pages 785-794

  Mezaki, Takahiro ^a  

^a Sakakibara Hakuho Hospital   (Japan)

Author keywords

Botulinum toxin; Molecular engineering; Remission; Therapy; Ultrasonography

Indexed keywords

BOTULINUM TOXIN A; COSMETIC;

BLEPHAROSPASM; CERVICAL DYSTONIA; ELECTROMYOGRAM; HEMIFACIAL SPASM; HUMAN; JAPAN; NERVE CELL; NERVE FIBER; NEUROMUSCULAR BLOCKING; PES EQUINUS; REVIEW; SPASTICITY; SUPERIOR OBLIQUE MUSCLE; SYNAPSE; ULTRASOUND;

BLEPHAROSPASM; BOTULINUM TOXINS; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; TORTICOLLIS;

EID: 79960729958     PISSN: 18816096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Kerner J: Das Fettgift oder die Fettsäure und ihre Wirkungen auf den thierischen Organismus, ein Beytrag zur Untersuchung des in verdorbenen Würsten giftig wirkenden Stoffes. Cotta, Stuttgart, 1822
2. Hirota N, Hirota M, Mezaki T: Dystonic frowning without blepharospasm. Parkinsonism Relat Disord 14: 579-580, 2008
3. Mezaki T: Dystonia redefined as central non-paretic loss of control of muscle action: a concept including inability to activate muscles required for a specific movement, or 'negative dystonia'. Med Hypotheses 69: 1309-1312, 2007
4. Nikolova ZT, Fellbrich A, Born J, Dengler R, Schröder C: Deficient recognition of emotional prosody in primary focal dystonia. Eur J Neurol 18: 329-336, 2010
5. Mezaki T: Unexpected serious adverse reactions to the therapy with botulinum toxin might be due to hypersensitivity. Med Hypotheses 73: 1076-1077, 2009
6. Moore AP, Ade-Hall RA, Smith CT, Rosenbloom L, Walsh HP, et al: Two-year placebo-controlled trial of botulinum toxin A for leg spasticity in cerebral palsy. Neurology 71: 122-128, 2008
7. Kanovsky P, Bares M, Severa S, Richardson A; Dysport Paediatric Limb Spasticity Study Group: Long-term efficacy and tolerability of 4-monthly versus yearly botulinum toxin type A treatment for lower-limb spasticity in children with cerebral palsy. Dev Med Child Neurol 51: 436-445, 2009
8. Tedroff K, Granath F, Forssberg H, Haglund-Akerlind Y: Long-term effects of botulinum toxin A in children with cerebral palsy. Dev Med Child Neurol 51:120-127, 2009
9. Fietzek U, Herrmann J, Mall V, Bigalke H, Geth K, et al: High prevalence of antibody formation against botulinum toxin A in the treatment of children: a long-term cohort study in the years 1993-2001. Neuropediatrics 35: V18, 2004
10. Herrmann J, Geth K, Mall V, Bigalke H, Schulte Mönting J, et al: Clinical impact of antibody formation to botulinum toxin A in children. Ann Neurol 55: 732-735, 2004
11. Graham HK: Re: response to Scheinberg et al. J Paediatr Child Health. 44: 469, 2008
12. Heinen F, Desloovere K, Schroeder AS, Berweck S, Borggraefe I, et al: The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol 14: 45-66, 2010
13. Fehlings D, Novak I, Berweck S, Hoare B, Stott NS, et al: Botulinum toxin assessment, intervention and follow-up for paediatric upper limb hypertonicity: international consensus statement. Eur J Neurol 17: 38-56, 2010
14. Love SC, Novak I, Kentish M, Desloovere K, Heinen F, et al: Botulinum toxin assessment, intervention and after-care for lower limb spasticity in children with cerebral palsy: international consensus statement. Eur J Neurol 17: 9-37, 2010
15. Wissel J, Ward AB, Erztgaard P, Bensmail D, Hecht MJ, et al: European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med 41: 13-25, 2009
16. Royal College of Physicians, British Society of Rehabilitation Medicine, Chartered Society of Physiotherapy, Association of Chartered Physiotherapists Interested in Neurology: Spasticity in Adults: Management Using Botulinum Toxin. National Guidelines. RCP, London, 2009
17. Sheean G, Lannin NA, Turner-Stokes L, Rawicki B, Snow BJ: Botulinum toxin assessment, intervention and after-care for upper limb hypertonicity in adults: international consensus statement. Eur J Neurol 17: 74-93, 2010
18. Olver J, Esquenazi A, Fung VS, Singer BJ, Ward AB: Botulinum toxin assessment, intervention and after-care for lower limb disorders of movement and muscle tone in adults: international consensus statement. Eur J Neurol 17: 57-73, 2010
19. Carruthers A: History of the clinical use of botulinum toxin A and B. Clin Dermatol 21: 469-472, 2003
20. http://sean.ping-pong.com/team/ryccadubuc/2007/07/09/history-of-botox- and-how-botox-works/
21. Kawashima M, Harii K: An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects. Int J Dermatol 48: 768-776, 2009
22. Hennenlotter A, Dresel C, Castrop F, Ceballos-Baumann AO, Wohlschläger AM, et al: The link between facial feedback and neural activity within central circuitries of emotion-new insights from botulinum toxin-induced denervation of frown muscles. Cereb Cortex 19: 537-542, 2009
23. Lewis MB, Bowler PJ: Botulinum toxin cosmetic therapy correlates with a more positive mood. J Cosmet Dermatol 8: 24-26, 2009
24. Finzi E, Wasserman E: Treatment of depression with botulinum toxin A: a case series. Dermatol Surg 32: 645-650, 2006
25. Havas DA, Glenberg AM, Gutowski KA, Lucarelli MJ, Davidson RJ: Cosmetic use of botulinum toxin-a affects processing of emotional language. Psychol Sci 21: 895-900, 2010
26. Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, et al; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 73: 1227-1233, 2009
27. Antonucci F, Rossi C, Gianfranceschi L, Rossetto O, Caleo M: Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci 28: 3689-3696, 2008
28. Currà A, Berardelli A: Do the unintended actions of botulinum toxin at distant sites have clinical implications? Neurology 72: 1095-1099, 2009
29. Bach-Rojecky L, Lacković Z: Central origin of the antinociceptive action of botulinum toxin type A. Pharmacol Biochem Behav 94: 234-238, 2009
30. Bach-Rojecky L, Salković-Petrisić M, Lacković Z: Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: bilateral effect after unilateral injection. Eur J Pharmacol 633: 10-14, 2010
31. Costantin L, Bozzi Y, Richichi C, Viegi A, Antonucci F, et al: Antiepileptic effects of botulinum neurotoxin E. J Neurosci 25: 1943-1951, 2005
32. Naumann M, Jankovic J: Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin 20: 981-990, 2004 (Pubitemid 38954460)
33. Mezaki T, Sakai R: Botulinum toxin and skin rash reaction. Mov Disord 20: 770, 2005 (Pubitemid 41051797)
34. Li M, Goldberger BA, Hopkins C: Fatal case of BOTOX® - related anaphylaxis? J Forensic Sci 50: 169-172, 2005
35. Mezaki T, Kaji R, Kohara N, Fujii H, Katayama M, et al: Comparison of therapeutic effecacies of type A and F botulinum toxins for blepharospasm: a double-blind, controlled study. Neurology 45: 506-508, 1995
36. Rohrbach S, Junghans K, Köhler S, Laskawi R: Minimally invasive application of botulinum toxin A in patients with idiopathic rhinitis. Head Face Med 5: 18, 2009
37. Giannantoni A, Santaniello E, Proietti S, Constantini E, Serva MR, et al: Intravesical passive delivery of botulinum A toxin in the treatment of idiopathic detrusor overactivity and painful bladder syndrome: a preliminary study. Urodinamica 17: 134-135, 2007